ACELYRIN, INC. Appoints Agnes Lee as Senior Vice President, Investor Relations and Corporate Communications
15 Febbraio 2024 - 10:05PM
ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma
company focused on accelerating the development and delivery of
transformative medicines in immunology, today announced the
appointment of Agnes Lee as Senior Vice President, Investor
Relations and Corporate Communications. Reporting to Founder and
CEO Shao-Lee Lin, MD, PhD, Ms. Lee will be responsible for leading
investor relations and corporate communications and will join the
company’s Senior Leadership Team.
“I am pleased to welcome Agnes to the ACELYRIN leadership team,”
said Dr. Lin. “Her deep expertise and strategic mindset augments
our already talented team to effectively convey our unique value
proposition to key stakeholders. With her proven track record of
fostering strong relationships with the investment community and
implementing effective communication strategies, Agnes further
strengthens our foundation for success as we seek to develop
transformative medicines for patients and deliver value to
shareholders.”
Ms. Lee most recently served as Senior Vice President of
Investor Relations and Strategic Planning at Inogen, Inc., where
she created an investor relations program to promote the company to
analysts and investors, and collaboratively led investor marketing
to reflect an evolution of the company’s vision and strategy.
Before Inogen, Ms. Lee served as Vice President of Investor
Relations at Butterfly Network Inc., where she was responsible for
building a global investor relations program to promote the company
to security analysts, institutional and individual shareholders, as
well as media. She also held similar roles of increasing
responsibilities at Fluidigm Corporation and ResMed Inc., a NYSE
and ASX dual-listed company. Ms. Lee began her investor relations
career at Life Technologies, which was acquired by Thermo Fisher
Scientific in 2014. Earlier in her career, she served as finance
manager at Celera Diagnostics and held investment banking roles at
Salomon Smith Barney and Bank of America Securities.
“I am honored to join ACELYRIN to lead the investor relations
and corporate communications functions as we progress on our
corporate journey in support of patients,” said Ms. Lee. “I look
forward to working closely with the leadership team as we continue
building on our important relationships with investors and
communicating the story of ACELYRIN’s future potential.”
Ms. Lee is currently a Board Member and Board Secretary of the
Association for Investor Relations (NIRI) San Diego Chapter, where
she has been a member of the board since 2020.
She holds a Master of Business Administration Degree in Finance
and Marketing from the Kellogg School of Management at Northwestern
University and a Bachelor of Arts Degree in Economics and
International Affairs from Indiana University Bloomington.
About ACELYRIN, INC.ACELYRIN, INC. (Nasdaq:
SLRN) is a Los Angeles area-based late-stage clinical biopharma
company – with additional operations in the San Francisco Bay area
– focused on providing patients life-changing new treatment options
by identifying, acquiring, and accelerating the development and
commercialization of transformative medicines.
For more information about ACELYRIN, visit us at
www.acelyrin.com or follow us on LinkedIn and X.
Forward Looking StatementsThis press release
contains forward-looking statements including, but not limited to,
statements related to the overall advancement of ACELYRIN’s
programs and ability to accelerate the development and delivery of
transformative medicines. These forward-looking statements are
based on ACELYRIN’s current plans, objectives and projections, and
are inherently subject to risks and uncertainties that may cause
ACELYRIN’s actual results to materially differ from those
anticipated in such forward-looking statements. Such risks and
uncertainties include, without limitation, those associated with
the successful completion of development and regulatory activities
with respect to ACELYRIN’s product candidates and other risks and
uncertainties affecting ACELYRIN including those described from
time to time under the caption “Risk Factors” and elsewhere in
ACELYRIN’s current and future reports filed with the Securities and
Exchange Commission, including its Quarterly Report on Form 10-Q
for the quarter ended September 30, 2023. Forward-looking
statements contained in this press release are made as of this
date, and ACELYRIN undertakes no duty to update such information
except as required under applicable law.
ACELYRIN
Contacts:investors@acelyrin.commedia@acelyrin.com
Grafico Azioni ACELYRIN (NASDAQ:SLRN)
Storico
Da Nov 2024 a Dic 2024
Grafico Azioni ACELYRIN (NASDAQ:SLRN)
Storico
Da Dic 2023 a Dic 2024